



FUND OBJECTIVE

The Global X Japan Bio & Med Tech ETF seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the FactSet Japan Bio & Med Technologies Index.

KEY FEATURES



High Growth Potential

The Global X Japan Bio & Med Tech ETF enables investors to access high growth potential through companies whose principal business is related to biomedical technologies.



Unconstrained Approach

The Global X Japan Bio & Med Tech ETF's composition transcends classic sectors, industries, and geographic classifications by tracking an emerging theme.



ETF Efficiency

In a single trade, the Global X Japan Bio & Med Tech ETF delivers access to dozens of companies with high exposure to the biomedical technologies theme.

FUND DETAILS


Inception Date	6/21/21
Underlying Index	FactSet Japan Bio & Med Technologies Index
Number of Holdings	27
Assets Under Management	¥ 5.66(100mil)
NAV (per 100 units)	¥ 164,508
Management Fee	0.649% per annum (0.59% before tax)
Distribution Frequency	Semi-Annually
Closing date	6/24, 12/24

TRADING DETAILS

Securities code	2639
ISIN	JP3049310000
Exchange	Tokyo Stock Exchange
Bloomberg INAV Ticker	2639JPIV
Index Ticker	FDSBMTF

ASSETS UNDER MANAGEMENT / FUND PERFORMANCE CHART

(6/21/2021 ~ 3/29/2024)



PREVIOUS 12-PERIODS DISTRIBUTIONS

per 100 units, before taxes (Yen)	
12/24/21	400
6/24/22	800
12/24/22	400
6/24/23	300
12/24/23	800
Total Distribution Since Inception	
	2,700

PERFORMANCE

	One Month	Year to Date	One Year	Three Year	Since Inception
FUND at NAV	-1.76 %	+3.64 %	+7.03 %	-----	-11.65 %
FUND at NAV (reinvestment)	-1.76 %	+3.64 %	+7.77 %	-----	-10.14 %
FactSet Japan Bio & Med Technologies Index (Total Return)	-1.71 %	+3.81 %	+8.62 %	-----	-8.32 %

TOP 10 HOLDINGS


		% of AUM	
		Total : 67.24%	
TERUMO CORP	8.86%	DAIICHI SANKYO CO LTD	7.08%
OLYMPUS CORP	8.16%	ASAHI INTECC CO LTD	7.02%
SHIMADZU CORP	8.14%	TAKEDA PHARMACEUTICAL CO LTD	5.46%
SYSMEX CORP	7.61%	NIHON KOHDEN CORP	3.82%
M3 INC	7.32%	SUZUKEN CO LTD	3.77%

Fund performance assumes that dividends (before taxes) are reinvested in the fund. NAV value is calculated after deducting trust fees. In the graph, the value of (FactSet Japan Bio & Med Technologies Index) is modified to match the fund NAV at the time of inception. The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. High short term performance of the fund is unusual and investors should not expect such performance to be repeated.



INDUSTRY BREAKDOWN

% of AUM



● Precision Instruments	36.18%
● Pharmaceutical	28.11%
● Electric Appliances	16.18%
● Services	10.14%
● Wholesale Trade	7.72%
● Foods	0.76%
● ---	---
● ---	---
● ---	---
● Others*	0.91%

*Others include cash and cash equivalents.

Concept & Key Points

1. Invest in Japanese Biotechnology and Medtech companies


2. Classify Biotechnology and Medtech into 4 sub-themes

- (1) MedTech Equipment
- (2) BioMed Services & Software
- (3) Biopharmaceuticals
- (4) Conglomerate Biopharmaceuticals

3. Free-float weighted market capitalization weights (up to 8 percent per stock)

4. Reconstitution and rebalancing portfolio, twice a year in January and July

Index construction process



Investment Risks

The Fund will invest in financial instruments whose prices fluctuate and as a result the NAV per unit of the Fund will also fluctuate. Therefore the invested amount will not be guaranteed and a loss of principal may be caused. All the gains and losses accrued to the trust assets will be attributable to the investors. Investment trusts are not deposits.

Major factors to cause fluctuation of NAV per unit:

Price Volatility risks / Credit risks (Stock Price Volatility), Other risks

The performance of the NAV may not completely match that of the index. The factors to cause fluctuation of NAV per unit are not limited to those mentioned above. Please read "Investment Risks" in the fund's Prospectus describing in detail.

Fee Structure

<Fees directly charged to customers>

Subscription commission: Determined by the Distributor. (Subscription Commission is a consideration for explanation of products, provision of product information and investment information, and execution of application at the time of the subscription of the Fund)

Redemption Fee: Nil

Exchange commission: Determined by the Distributor.

(Exchange Commission is a consideration for administrative procedures for exchange of units of the Fund.)

<Fees indirectly charged during holding period>

Management Fee (Trust Fee):

Trust fee is calculated daily as sum of 1 and 2 as shown below during the holding period.

1. The amount obtained by multiplying the total net assets of the trust assets by the ratio up to 0.649% per annum (0.59% before tax).
2. The amount obtained by multiplying lending charges due to lending of stocks held in the trust assets by up to 55% (50% before tax).

Other Expenses and Brokerage Commissions

Fund Listing Expenses and Annual Fees for Use of Trademarks of the Index with tax levied on them can be borne by the unitholders, and can be paid from the trust assets.

Commissions associated with securities transactions (including brokerage commissions on trade of securities, fees for future transactions and option transactions) and auditing fees shall be charged to the trust assets.

※As expenses for brokerage commissions on trade of securities, etc. shall vary depending on circumstances, specific rate of fees or the maximum amounts thereof cannot be disclosed in advance.

※Please see further details described under "Expenses and Taxes of the Fund" in the Prospectus.

About the copyright of the index

FACTSET DOES NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE FACTSET JAPAN BIO & MED TECHNOLOGIES INDEX OR ANY DATA INCLUDED THEREIN AND LICENSOR SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. FACTSET MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY LICENSEE, OWNERS OF THE PRODUCT, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE FACTSET JAPAN BIO & MED TECHNOLOGIES INDEX OR ANY DATA INCLUDED THEREIN. FACTSET MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE FACTSET JAPAN BIO & MED TECHNOLOGIES INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL FACTSET HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

Disclaimer: Warning before handling this material

This material was prepared by Global X Japan Co. Ltd. to provide information about its funds' performance and other operation-related facts. Potential investors should refer to and read the prospectus of such fund product for more detailed information prior to their investment decision. Since investment trusts will invest in stocks whose prices fluctuate, the NAV of this fund could possibly decline and cause a loss in investment. The investors' principals thus are not guaranteed and the fund contains risk that the NAV may fall below its par value. All the gains and losses accrued to the trust assets will be attributable to the investors. Investment trusts are different from deposits and insurance policies. Investment trusts are not protected by the Deposit Insurance Corporation of Japan and insurance policyholders protection corporations. Investment trusts which are not purchased from securities companies are not protected by the Japan Investor Protection Fund. The information, statements, forecasts and projections contained herein, including any expression of opinion, are based upon sources believed to be reliable, but their accuracy, correctness or completeness are not guaranteed. The performance of investments, if referred to herein, is based on past data and is neither necessarily an indication nor a guarantee of future performance of investments. The performance data in this material does not consider any tax or fees if there were any, and will not provide a final return for potential investors. Global X Japan Co. Ltd. made all reasonable efforts to ensure that the information contained herein is current, but it is subject to change without notice. The dividend amount is to be determined, based on the dividend distribution policy of such fund product, by the investment manager, who will not promise or guarantee any fixed amount of dividend before investment. In some cases, the investment manager might decide to skip a dividend payment for the correspondent period due to performance reason. Global X is a registered trademark of Global X Management Company LLC. Any replication, citation, reprinting, transmission or otherwise of Global X – by any means and for any purpose – without permission is prohibited. Global X LLC is a registered investment advisor with the United States Securities and Exchange Commission.



Global X Japan Co. Ltd. Registration No. : Director of Kanto Local Finance Bureau (Financial Instruments Firms) No.3174 Member of Japan Investment Advisers Association Member of The Investment Trusts Association, Japan

Sanno Park Tower 21F, 2-11-1, Nagatacho, Chiyoda-ku, Tokyo